1 / 23

Blood Pressure and Drugs

Blood Pressure and Drugs. Sarah Fu (sarah.fu@mail.utoronto.ca) Meng Xue Shi (mengxue.shi@mail.utoronto.ca) Shuhua Situ (shuhua.situl@mail.utoronto.ca) Monica Tran (mo.tran@mail.utoronto.ca) Presentation Date: Friday, September 21, 2012. PHM142 Fall 2012

ryder
Download Presentation

Blood Pressure and Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Blood Pressure and Drugs Sarah Fu (sarah.fu@mail.utoronto.ca) Meng Xue Shi (mengxue.shi@mail.utoronto.ca) Shuhua Situ (shuhua.situl@mail.utoronto.ca) Monica Tran (mo.tran@mail.utoronto.ca) Presentation Date: Friday, September 21, 2012 PHM142 Fall 2012 Instructor: Dr. Jeffrey Henderson

  2. Blood Pressure • Measure of systolic and diastolic pressure • Pressure against the blood vessels • Proportional to blood flow • Transport of nutrients and O2 • Removal of waste and CO2 • Distribution of Hormones

  3. Hypertension • Blood pressure above 140/90 • Risk increases with age • 2011 – 44% men and women ages 45-64 • 2011 – 45% men and women ages 65+

  4. Dangers of Hypertension • Blindness • Stroke • Heart attack • Heart failure • Kidney damage • High salt diet • Obesity • Hereditary • Stress Causes

  5. Renin-Angiotensin Aldosterone System

  6. ACE Inhibitors Liver A H H A: Enalapril

  7. ACE Inhibitors Liver A B H H A: Enalapril B: Esterase

  8. ACE Inhibitors Liver B A H H A: Enalapril B: Esterase

  9. ACE Inhibitors Liver B A H H A: Enalapril B: Esterase

  10. ACE Inhibitors Liver B A H H A: Enalapril B: Esterase

  11. ACE Inhibitors Liver B H C H H B: Esterase C: Enalaprilat

  12. ACE Inhibitors Action of Benazeprilat H H H

  13. Adverse effects <1% during clinical trials • Hypotension • Chest pain • Abdominal pain • Anemia >1% during clinical trials • Fatigue • Headache • Dizziness • Nausea

  14. Hypotension • Common in institutionalized elderly • Orthostatic Hypotension • baroreflex failure or volume depletion • Systolic bp decrease >20mm Hg • Diastolic bp decrease >10mm Hg • Associated with hypertension, increased age and diabetes mellitus

  15. Orthostatic Hypotension • Symptoms • Blurred vision, headache, nausea, dizziness • Risks • Increased incident of cerebral vascular disease • Mild cardio-infarction • Coronary heart disease • Heart failure • Cardio-vascular mortality

  16. Treatments • Medicinal • Pyridostigmine (Mestinon) • Fludrocortisone (Florinef) • Midodrine (ProAmatine) • Non-Medicinal • Consumption of salt • Consumption of extra fluids • Head of bed elevated • Physical Activity • Abdominal binder

  17. Midodrine • Vasopressor • Increases standing systolic bp • Metabolite desglymidodrine • α1-agonist • Activation of α-adrenergic receptors • Arterial and venous vasoconstriction • Elevates blood pressure

  18. Enzymatic cleavage Midodrine Desglymidodrine Glycine Desglymidodrine Vasoconstriction – Increase BP  γ α β α1-adrenergic receptor s Cytosol Phospholipase C Increase in calcium Nucleus

  19. Adverse Effects • Supine hypertension • Scalp paresthesias • Pilomotor reactions (goosebumps) • Urinary urgency • Headaches

  20. Hypotension Summary • Systolic BP drop >20mm Hg or diastolic BP drop >10mm Hg • Midodrine: major metabolite desglymidodrine which activates adrenergic receptors • Vasopressor effect that causes activation and constriction of the arterial system Hypertension Hypertension: BP > 140/90 ACE converts angiotensin I (inactive) into angiotensin II (active) to increase blood pressure Angiotensin II is responsible for vasoconstriction, thirst, and releases aldosterone for retention of Na+ Majority of ACE inhibitors (Enalapril), when activated, bind by the carbonyl group Enalaprilat (active form) inhibits ACE, which vasoconstriction, thirst, and stops the release of aldosterone

  21. References • Ace Inhibitors. 09/15/12. <<http://www.uic.edu/classes/pcol/pcol425/restricted/Skidgel/ACE%20Inhibitors%20handout%202011.pdf>. • Adrenal Gland. <http://te-deum.blogspot.ca/2012/08/recovering.html>. • Barrios, V., Escobar, C., (2010). Antihpertensive and organ-protective effects of benazepril. Expert Review of Cardiovascular Therapy, 12, 1653-1724. • Burt, V.L., Whelton, P., Roccella, E.J., Brown, C., Cutler, J.A., Higgins, M., … Labarthe, D. (1995). Prevalence of hypertension in the US adult population. Hypertension, 25, 305-313. • Canadian Health Measures Survey: Blood pressure in adults. 09/13/12. <http://www.statcan.gc.ca/daily-quotidien/100217/dq100217b-eng.htm>. • eCPS. 09/15/12. <https://www-e-therapeutics-ca.myaccess.library.utoronto.ca/cps.showMonograph.action#>. • Figueroa, J.J., Basford, J.R., and Low, P.A., (2010). Preventing and treating orthostatic hypotension: As easy as A, B, C. Cleveland Clinic Journal of Medicine, 7(5), 298-306 • High blood pressure, by age group and sex. 09/15/12. <http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health03a-eng.htm>. • Hypertension in Canada, 2010. 09/15/12. <http://www.phac-aspc.gc.ca/cd-mc/cvd-mcv/ccdss-snsmc-2010/pdf/CCDSS_HTN_Report_FINAL_EN_20100513.pdf>. • Jabary, N.S., Sarabia, R., Sanchez, T., and Gordillo, R. (2007). Midodrine treatment in the management of severe orthostatic hypotension after hemangioblastoma surgery. ActaNeurochirurgica, 149, 303-306 • Kaplan, N.M., & Victor, R.G. (2009). Kaplan’s Clinical Hypertension (10th ed.). Philadelphia: WoltersKluwer • Liver. 09/13/12. <http://www.pawelmazur.org/blog/wp-content/uploads/2010/07/liver.jpg>. • Nature of Code Blood Vessels. 09/13/12. <http://itp.nyu.edu/~ek1388/myblog/?p=904>. • Oldenburg, O., Kribben, A., Baumgart, D., Philipp, T., Erbel, R., and Cohen, M. V., (2002). Treatment of orthostatic hypotension. Current Opinion in Pharmacology, 740-746 • Perazella, M.A. (2003). Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension. Expert Opinion Drug Safety, 2(1), 37-47 • Sherwood, L. (2007). Human Physiology (6th ed.). Belmont: Thomson Broks/Cole. • Swann, P., Stehouwer, M., and Tukker, J., (1995). Molecular mechanism for the relative binding affinity to the intentinal peptide carrier. Comparion of three ACE-inhibitors: enalapril, enalaprilat, and isinopril. Biochimica et BiophysicaActa, 1236, 31-38.

More Related